pd 98059 and azd 6244

pd 98059 has been researched along with azd 6244 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cai, H; Chen, L; Chen, Z; Li, C; Li, S; Li, Y; Long, D; Luo, F; Rao, L; Yang, H; You, G; Zhang, Q	1

Other Studies

1 other study(ies) available for pd 98059 and azd 6244

Article	Year
Selumetinib, an Oral Anti-Neoplastic Drug, May Attenuate Cardiac Hypertrophy via Targeting the ERK Pathway. PloS one, 2016, Volume: 11, Issue:7 Topics: Administration, Oral; Animals; Antineoplastic Agents; Aorta; Apoptosis; Benzimidazoles; Cardiomegaly; Constriction, Pathologic; Disease Models, Animal; Electrocardiography; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gene Expression Regulation; MAP Kinase Signaling System; Myocytes, Cardiac; Proto-Oncogene Proteins c-akt; Rats; Stress, Physiological; Swimming	2016

Article

Year

Selumetinib, an Oral Anti-Neoplastic Drug, May Attenuate Cardiac Hypertrophy via Targeting the ERK Pathway.

PloS one, 2016, Volume: 11, Issue:7

Topics: Administration, Oral; Animals; Antineoplastic Agents; Aorta; Apoptosis; Benzimidazoles; Cardiomegaly; Constriction, Pathologic; Disease Models, Animal; Electrocardiography; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gene Expression Regulation; MAP Kinase Signaling System; Myocytes, Cardiac; Proto-Oncogene Proteins c-akt; Rats; Stress, Physiological; Swimming

2016